A Baseline Prediction Model for First-Year CPAP Treatment Disengagement in Adults with Obstructive Sleep Apnea: A Secondary Analysis of a Danish Cohort
Aug 2026· Patient Preference and Adherence· Vol 20, pp. 1-13· 0 citations· 22 references
Medicine
TL;DR
Three routinely available baseline measures provided moderate predictive information, while broader and penalized models offered no consistent improvement, and provide a fixed-horizon benchmark for external validation in contemporary CPAP cohorts that directly assess device use, treatment preferences, and treatment burden.
Abstract
Purpose To estimate and internally evaluate a fixed baseline model for recorded first-year continuous positive airway pressure (CPAP) treatment disengagement before device-use data are available and compare it with more complex alternatives. Patients and Methods We conducted a secondary analysis of a Danish single-center cohort that initiated CPAP in 2012–2013. The outcome was the recorded 52-week treatment-status event, which did not distinguish active discontinuation from loss to follow-up. Of 695 participants, 662 had determinate status and 94 events. The fixed logistic model included current smoking, Epworth Sleepiness Scale (ESS) score, and apnea–hypopnea index (AHI), with coefficients estimated in 632 complete cases (85 events). Performance was evaluated by repeated 10-fold cross-validation with bootstrap confidence intervals (CIs). Results Current smoking was associated with higher odds of the recorded outcome (odds ratio [OR] 2.45, 95% CI 1.47–4.07). Higher ESS (OR per 5-point increase, 0.68; 95% CI, 0.53–0.87) and AHI (OR per 10 events/hour increase, 0.56; 95% CI, 0.45–0.68) were associated with lower odds. The cross-validated area under the curve was 0.762 (95% CI, 0.709–0.812), the Brier score was 0.103 (0.087–0.119), the calibration intercept was −0.001 (−0.259 to 0.226), and the calibration slope was 0.927 (0.624–1.298). In 662 participants, extended and full models did not consistently improve prediction error. The 94 events could not be separated into active discontinuation and loss to follow-up. Conclusion Three routinely available baseline measures provided moderate predictive information, while broader and penalized models offered no consistent improvement. These findings provide a fixed-horizon benchmark for external validation in contemporary CPAP cohorts that directly assess device use, treatment preferences, and treatment burden.
Among those with moderate-to-severe OSA identified through population screening, most accepted evaluation and PAP treatment, with approximately half becoming long-term users, suggesting that population-based detection of OSA followed by routine clinical management is feasible.
E. H. Thorarinsdottir, B. Benediktsdóttir, T. Aspelund et al.· BMJ Open· 0 citations
BACKGROUND
Continuous Positive Airway Pressure (CPAP) is the standard treatment of obstructive sleep apnea (OSA), but has a heterogeneous blood pressure (BP) lowering effect. We hypothesized that Ventilatory Burden (VB), a metric better reflecting the entire burden of pathological airflow, may predict CPAP-induced BP r...
Wen-Tao Wu, Li-Mei Mao, A. Parekh et al.· Sleep Medicine· 0 citations
Models incorporating baseline ESS and either ventilatory burden or AHI predict ESS improvement and may help identify patients with OSA likely to benefit from CPAP.
E. Staykov, J. Töyräs, D. Mann et al.· Sleep· 0 citations
BACKGROUND
Obstructive sleep apnea (OSA) is highly prevalent among patients with heart failure with preserved ejection fraction (HFpEF). The aim of this study was to analyze the poorly characterized independent impact of OSA on short-term readmission and in-hospital outcomes among hospitalizations with HFpEF.
METHODS...
R. Peesapati, Katyayani Saripalli· Proceedings· 0 citations
Among the physiological parameters recorded during PAP titration, the lowest SpO2 was the most robust predictor of short-term adherence, independent of both baseline disease severity and baseline hypoxemia.
Jayoung Oh, Ji H. Choi· Life· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.